The University of Oslo is Norway’s oldest and highest rated institution of research and education with 28 000 students and 7000 employees. Its broad range of academic disciplines and internationally esteemed research communities make UiO an important contributor to society.

Centre for Molecular Medicine Norway (NCMM, was established in 2008 as a partner institution of the European Molecular Biology Laboratory ( and together with nodes in Finland (FIMM), Sweden (MIMS) and Denmark (Dandrite) form the Nordic EMBL Partnership for Molecular Medicine. NCMM is a joint venture between the University of Oslo, Health Region South-East and the Research Council of Norway. NCMM is located in new laboratories in the University of Oslo and Oslo University Hospital Biomedical Campus in the Oslo Research Park. From January 2017 NCMM is merged with the Biotechnology Centre of Oslo. The new NCMM consists of two departments: NCMM Translational Research (former NCMM) and NCMM Biotechnology (former BiO) with altogether 11 research groups. The overall objective of NCMM is to conduct cutting edge research in molecular medicine and biotechnology as well as facilitate translation of discoveries in basic medical research into clinical practice. The Centre serves as a green-house for young scientists.
Centre for Molecular Medicine Norway (NCMM)
Post-Doctoral Research Fellowship in Tumor Immunology

NCMM focuses particularly on disease mechanisms where Norway has clear strengths and investigates disease mechanisms in cancer, immune disorders and cardiovascular diseases.

The Taskén group at NCMM investigates signal networks and targeting strategies in immune cells and cancer cells as well as T cell immune regulation and the role in tumor immunology. The group has established the Chemical Biology Screening Platform that serves the Oslo region and is now also starting projects pursuing different targets in cancer and immune cells. At the moment we are searching for a postdoctoral fellow:

Post-doctoral research fellow – Tumor immune evasion mechanisms

A position is open for a postdoc on a project funded by the Norwegian Cancer Society with focus on molecular mechanisms of tumor immune evasion by prostaglandin E2 and regulatory T cells. We are capitalizing on new technologies developed in the group and will pursue an ambitious plan to do both systems level analyses and development of tools that disrupt signal complexes that would reverse suppression of anti-tumor immunity at the level of PGE2 action and specific cAMP signalling units, as well as at the level of Treg action, both with potential therapeutic applications. Furthermore, we will examine cross-talk with other established immune therapies such as immune checkpoint inhibitors and CAR-therapy in experimental models.

Post-doctoral candidate:

We seek highly motivated individuals holding a Ph.D. that appreciate working in an international and interactive environment. The ideal candidate should have a strong background in chemical biology, cell biology, cancer biology or T cell immunology and a specific interest in working in translational research. Advanced skills in one or more of the areas of chemical biology screening, flow cytometry, signaling analyses using flow-based assays, biochemical and immunological methods and cellular work is required. A FELASA C license for animal experimentation would be a benefit.

University of Oslo has an agreement for all employees, aiming to secure rights to research results and intellectual property.

The postdoctoral-position will be placed as SKO 1352 post-doctoral research fellow, with salary range depending on qualifications: step 57 - 65 (NOK 486 100 – 567 100). The position is for three years externally funded from the Norwegian Cancer Society and with preferred start as soon as possible and within the first half of 2017.


For further information about the group, see



About the position: Director, Professor Kjetil Taskén ( Inquiries regarding technical aspects of the application can be directed to Nina Modahl (


The application should include a cover letter summarizing the applicant’s career and past research accomplishments (1-2 pages), CV and a list of publications, copies of certificates and grades, and names of three references.


Please submit your application through the web-based recruitment system linked here:

  • Region:
  • Oslo
  • Job type:
  • Contract
  • Working hours:
  • Full-time
  • Working days:
  • Day
  • Application deadline:
  • 04/04/2017
  • Expected Start Date:
  • as soon as possible and within the first half of 2017
  • Reference number:
  • 2017/3454